Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

被引:70
作者
Murphy, PS
Viviers, L
Abson, C
Rowland, IJ
Brada, M
Leach, MO
Dzik-Jurasz, ASK
机构
[1] Inst Canc Res, Canc Res UK Clin Magnet Resonance Res Grp, Sutton SM2 5PT, Surrey, England
[2] Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England
[3] Inst Canc Res, Acad Dept Neurooncol, Sutton SM2 5PT, Surrey, England
基金
英国医学研究理事会;
关键词
magnetic resonance spectroscopy; low-grade glioma; temozolomide; treatment response;
D O I
10.1038/sj.bjc.6601593
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic resonance spectroscopy (H-1-MRS) and imaging were incorporated into a study of patients receiving temozolomide therapy for low-grade glioma in order to evaluate and monitor tumour metabolite and volume changes during treatment, Patients (n = 12) received oral temozolomide (200 mg m(-2) day(-1)) over 5 days on a 28-day cycle for 12 cycles. Response assessment included baseline and three-monthly magnetic resonance imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour size. Short (TE (echo time) = 20 ms) and long (TE = 135 ms) echo time single voxel spectroscopy was performed in parallel to determine metabolite profiles. The mean tumour volume change at the end of treatment was -33% (s.d. = 20). The dominant metabolite in long echo time spectra was choline. At 12 months, a significant reduction in the mean choline signal was observed compared with the pretreatment (P = 0.035) and 3-month scan (P = 0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and may reflect the therapeutic effect of temozolomide.
引用
收藏
页码:781 / 786
页数:6
相关论文
共 24 条
[1]  
Barba I, 1999, CANCER RES, V59, P1861
[2]   Primary brain tumours in adults [J].
Behin, A ;
Hoang-Xuan, K ;
Carpentier, AF ;
Delattre, JY .
LANCET, 2003, 361 (9354) :323-331
[3]   Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies [J].
Brada, M ;
Judson, I ;
Beale, P ;
Moore, S ;
Reidenberg, P ;
Statkevich, P ;
Dugan, M ;
Batra, V ;
Cutler, D .
BRITISH JOURNAL OF CANCER, 1999, 81 (06) :1022-1030
[4]   Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas [J].
Brada, M ;
Viviers, L ;
Abson, C ;
Hines, F ;
Britton, J ;
Ashley, S ;
Sardell, S ;
Traish, D ;
Gonsalves, A ;
Wilkins, P ;
Westbury, C .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1715-1721
[5]   Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse [J].
Brada, M ;
Hoang-Xuan, K ;
Rampling, R ;
Dietrich, PY ;
Dirix, LY ;
Macdonald, D ;
Heimans, JJ ;
Zonnenberg, BA ;
Bravo-Marques, JM ;
Henriksson, R ;
Stupp, R ;
Yue, N ;
Bruner, J ;
Dugan, M ;
Rao, S ;
Zaknoen, S .
ANNALS OF ONCOLOGY, 2001, 12 (02) :259-266
[6]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[7]   THE TREATMENT OF OLIGODENDROGLIOMAS AND MIXED OLIGODENDROGLIOMA-ASTROCYTOMAS WITH PCV CHEMOTHERAPY [J].
GLASS, J ;
HOCHBERG, FH ;
GRUBER, ML ;
LOUIS, DN ;
SMITH, D ;
RATTNER, B .
JOURNAL OF NEUROSURGERY, 1992, 76 (05) :741-745
[8]   Low-grade oligodendroglioma responds to chemotherapy [J].
Mason, WP ;
Krol, GS ;
DeAngelis, LM .
NEUROLOGY, 1996, 46 (01) :203-207
[9]   In vivo H-1 MRS choline: Correlation with in vitro chemistry histology [J].
Miller, BL ;
Chang, L ;
Booth, R ;
Ernst, T ;
Cornford, M ;
Nikas, D ;
McBride, D ;
Jenden, DJ .
LIFE SCIENCES, 1996, 58 (22) :1929-1935
[10]   N-ACETYL-L-ASPARTIC ACID CONTENT OF HUMAN NEURAL TUMORS AND BOVINE PERIPHERAL NERVOUS TISSUES [J].
NADLER, JV ;
COOPER, JR .
JOURNAL OF NEUROCHEMISTRY, 1972, 19 (02) :313-&